clinical trial · NCT06741644
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
Advanced Solid TumorsCS2009CS2009PemetrexedCarboplatinPaclitaxelEtoposideNab-paclitaxelOxaliplatin
brief summary
This is a first-in-human (FIH), open-label, and multi-center Phase I/II study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of CS2009 as Monotherapy and Combination Therapy in Participants with Advanced Solid Tumors. The study is comprised of a Phase I dose escalation and Phase II dose expansion.
started
Feb 24, 2025
primary completion
Jan 1, 2027
completion
Jan 1, 2028
last updated
Apr 15, 2026
official title
A Phase I/II, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CS2009, a Tri-specific Antibody Targeting PD-1/VEGFA/CTLA-4, as Monotherapy and Combination Therapy in Participants With Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol